Home Contact Us 中文 English
Yourlocation:Home >News> Trimebutine maleate and Xiangshayangwei combination pill to treating functional dyspepsia

Trimebutine maleate and Xiangshayangwei combination pill to treating functional dyspepsia

Time:2015/9/30 7:19:10


Abstract Objective To observe Trimebutine maleate Xiangshayangwei pill combination treatment of functional dyspepsia (FD) its clinical efficacy. Methods of diagnosis of 62 cases of FD were divided into treatment group 32 cases, taking Trimebutine maleate, Xiangshayangwei pill treatment, 30 cases in the control group taking Trimebutine maleate treatment, surrounded for a course. Results The treatment group and 87.5% in the control group was 60.0%, compared the two groups, the difference was significant, P <0.05. Conclusion Trimebutine maleate Xiangshayangwei pill combination treatment was significantly better than the simple use of FD Trimebutine maleate.


Key words functional dyspepsia, Trimebutine maleate, Xiangshayangwei pill


With the continuous improvement of people's living standards, dietary conditions, accelerated pace of life, work, and mental pressures, functional dyspepsia (FD) incidence increased year by year, epidemiological data show that, accounting for 20 gastrointestinal clinics ~ 40%, clinical manifestations of upper abdominal pain, belching, early satiety, loss of appetite, nausea and vomiting, abdominal fullness and discomfort, sustainable or recurrent symptoms, quality of life is an important disease, is a common community clinics disease, we in June 2009 - June 2011 application Trimebutine maleate Xiangshayangwei pill combination therapy FD, a significant effect, are as follows:

1 The clinical data

1.1 Case selection and treatment assignment, all patients were higher hospital diagnosed, and treatment of FD back to the community were randomly divided into treatment group of 32 patients, including 13 males and 19 females, aged 20 to 61 years, mean 36 years; control group of 30 cases, including 12 males and 18 females, aged 21 to 65 years, mean 34.5 years, the shortest duration of 2 patients 6 months, the longest 16 years.

1.2 FD diagnostic criteria: ① have upper abdominal pain, epigastric burning, postprandial fullness, early satiety, and one or more symptoms of, was persistent or recurrent chronic process lasts up to three months (see FD Rome Ⅲ diagnostic Standard) or the onset of more than four weeks; ② endoscopic findings within normal or excluded erosion, ulcers and tumors and other organic disease; ③ laboratory, B ultrasound and X-ray inspection exclude hepatobiliary, pancreatic disorders.

1.3 Treatment: Treatment Suite US Buting 100mg, 3 times a day, taking 30 minutes before a meal, Xiangshayangwei pill (Henan Rendezvous pharmaceutical production) 6g, 3 times a day, taking 30 minutes before a meal; the control group clothes Trimebutine maleate 100mg, three times a day, taking 30 minutes before a meal, the same two basic treatment group, are four weeks for a course of gastric acid and epigastric burning sensation more evident in patients can be added with H2 receptor antagonists or proton pump inhibitors.

1.4 The evaluation, cured: clinical symptoms disappeared within six months without recurrence withdrawal effectively; clinical symptoms disappeared within six months withdrawal there recurrence, invalid; significantly improve the clinical symptoms, after stopping there recurrence, or no significant improvement in symptoms.

1.5 statistical methods using X2 test, P <0.05 considered statistically significant.

2 Results

After 4 weeks of treatment, the treatment group and 87.5% in the control group was 60.0%, the treatment group than the control group, the difference was statistically significant (P <0.05), see table.

3 Discussion

FD refers to having symptoms from the stomach and duodenum disorders caused these symptoms after tests to exclude organic disease a clinical syndrome, its etiology pathogenesis has not yet entirely clear, may be related to many factors : Numerous clinical studies have shown that the pathophysiology of FD may be related to gastric motility disorders, stomach paresthesia, closely related to gastric dysrhythmia and other stomach-derived factor; and psychosocial factors has been considered closely related to the pathogenesis of FD, FD patients the existence of abnormal personality, anxiety, depression was significantly higher than normal integration; in addition, about half of FD patients with Helicobacter pylori infection and chronic gastritis liver caused thereby, but whether there is some correlation, so far unknown. But pathophysiological changes of gastric motility disorders may be the primary mechanism for the pathogenesis of FD. Therefore, prokinetic agent has been the drug of choice in patients with FD, Trimebutine maleate maleate is a new generation of gastrointestinal motility regulating agents, is a opioid receptor agonist, it does not directly effect through central role in gastrointestinal smooth muscle to regulate gastrointestinal dysfunction. Acting on the outer periphery of the gastrointestinal tract plexus opioid receptors, have excitatory and inhibitory digestive tract duality, enabling hyperactivity, gastrointestinal movement from the low two-way adjustment. Xiangshayangwei pill by the rugosa, woody, Amomum, product shell, Atractylodes, Citrus, Magnolia composition, Chinese medicine studies suggest that prescription woody, product shell, orange peel, Amomum can gastrointestinal smooth muscle excitability, contractility strengthen motility speed, it can improve gastric motility disorders, relieve gastrointestinal flatulence caused by abdominal pain, bloating, hiccups; Amomum, dried tangerine peel, Agastache, Atractylodes with the promotion of the role of gastric secretion of digestive juice, increase digestion, and Magnolia officinalis has an antibacterial effect against a variety of bacteria, can improve gastrointestinal inflammatory conditions, gastrointestinal nerve sedative and Agastache, therefore, can relieve mental factors on the gastrointestinal nerves, improve the gastrointestinal symptoms. I believe that the two combined treatment is more effective mitigation FD upper gastrointestinal symptoms, reduce recurrence.


Related news